Alterity Therapeutics (ASX:ATH) has announced that its Phase 2 trial of ATH434 for treating patients with Multiple System Atrophy is now open for enrollment in Italy. …
Alterity Therapeutics launches ATH434 Phase 2 clinical trial in Italy
January 26, 2023 Australian Biotech
Latest Video
New Stories
-
The 'Week in Review' - 27 January
January 27, 2023 - - Podcast -
Forget about experts and terms of reference until we get a transparent process
January 27, 2023 - - Latest News -
Australia Day recognition for senior officials and pharmacy leaders
January 27, 2023 - - Latest News -
Is this a change of heart from the former health department secretary?
January 27, 2023 - - Latest News -
New chair for Australian genomics industry organisation
January 26, 2023 - - Australian Biotech -
MEDLAB receives Import Certificate from UK Home Office for NanaBis
January 26, 2023 - - Australian Biotech -
Alterity Therapeutics launches ATH434 Phase 2 clinical trial in Italy
January 26, 2023 - - Australian Biotech